Stockscreener 앱 받기
227.70
0.02%
0.04
전일 마감가:
$227.66
열려 있는:
$226.85
하루 거래량:
2.61M
Relative Volume:
0.45
시가총액:
$402.65B
수익:
$59.64B
순이익/손실:
$2.36B
주가수익비율:
171.81
EPS:
1.3253
순현금흐름:
$19.68B
1주 성능:
-3.63%
1개월 성능:
+0.07%
6개월 성능:
+24.37%
1년 성능:
+24.37%
1일 변동 폭
$225.51
$228.09
1주일 범위
$225.51
$237.62
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.82 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,073.50 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.00 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
130.34 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.55 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi - Benzinga
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Trea - GuruFocus
AbbVie Announces Positive Reimbursement Recommendations for SKYRIZI® in Ulcerative Colitis by Canada's Drug Agency - Quiver Quantitative
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - MarketScreener
3 Dividend-Paying Stocks that Are Up Over 30% in 2025 - Tokenist
AbbVie Unit Fails To Revive Dermal Filler Patent On Appeal - Law360
AbbVie (ABBV) Stock Price, Quote, News & History - Benzinga
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights - Yahoo Finance
Medicare negotiates discounts on two AbbVie drugs - Crain's Chicago Business
Is AbbVie Stock Outperforming the Nasdaq? - Yahoo Finance
CollPlant's Strategic Focus with AbbVie (ABBV) Gains Spotlight - GuruFocus
Pacific Wealth Management's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec - Investing News Network
BioMed X, AbbVie Launch New Research Project Focused on Anhedonia - Contract Pharma
AbbVie Inc (NYSE:ABBV) Shares Edge Lower Following Sector Review - Kalkine Media
IgG4-related disease Market Size was USD 170 million in 2024, estimates DelveInsight | Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Takeda - Barchart.com
How Recent Developments Are Shaping Analyst Views on AbbVie’s Future Edge - Yahoo Finance
Full FDA Approval of EPKINLY Combo Therapy Could Be a Game Changer for AbbVie (ABBV) - Yahoo Finance
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference - Investing News Network
AbbVie (NYSE: ABBV) to Join Piper Sandler 37th Conference Chat at 7:30 a.m. CT - Stock Titan
AbbVie Insiders Sell US$41m Of Stock, Possibly Signalling Caution - Yahoo Finance
The Zacks Analyst Blog JPMorgan, Netflix, AbbVie and Ohio Valley Banc - Yahoo Finance
Total debt per share of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV - TradingView
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Top Research Reports for JPMorgan Chase, Netflix & AbbVie - Yahoo Finance
ABBV latest news: price expected to consolidate near highs — upside breakout may target $240 - Traders Union
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs - MSN
How AbbVie Inc. stock performs in easing cycles2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Lip Augmentation Market to Witness Massive Growth by 2032 | - openPR.com
How AbbVie Inc. stock compares with tech leadersJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Unpacking the Latest Options Trading Trends in AbbVieAbbVie (NYSE:ABBV) - Benzinga
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressure - newser.com
The Escalator: AbbVie, Sonoma Biotherapeutics, Way Better Partners and more - Medical Marketing and Media
Is AbbVie Inc. (4AB) stock a buy before earnings resultsWeekly Stock Recap & Weekly Return Optimization Alerts - newser.com
How supply chain issues affect AbbVie Inc. stockPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Will AbbVie Inc. (4AB) stock profit from AI boomChart Signals & Reliable Price Action Trade Plans - newser.com
Why AbbVie Inc. stock appears on watchlistsMarket Performance Summary & Fast Moving Stock Watchlists - newser.com
Why millennials buy AbbVie Inc. (Common Stock) (4AB0) stockPortfolio Performance Summary & Short-Term High Return Ideas - newser.com
How geopolitical risks impact AbbVie Inc. (Common Stock) (4AB0) stock2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Can AbbVie Inc. stock weather global recession2025 Price Momentum & Smart Money Movement Tracker - newser.com
Why AbbVie Inc. (4AB) stock stays resilientShare Buyback & Verified Entry Point Detection - newser.com
How higher bond yields impact AbbVie Inc. stockEarnings Risk Report & AI Driven Stock Reports - newser.com
Is AbbVie Inc. stock undervalued at current priceJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Is AbbVie Inc. stock undervalued vs historical averagesTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionInflation Watch & Daily Oversold Bounce Ideas - newser.com
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Can AbbVie Inc. stock sustain revenue growthDay Trade & Smart Allocation Stock Tips - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthIPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.00%
자본화:
|
볼륨(24시간):